期刊文献+

硼替佐米联合化疗治疗多发性骨髓瘤的疗效观察 被引量:4

原文传递
导出
摘要 多发性骨髓瘤(MM)是难以治愈的恶性浆细胞增殖性疾病。有研究表明提高缓解质量[争取完全缓解(CR)]将延长患者的无进展生存(PFS)时间,并一定程度上延长患者的生存时间。近年来一些安全、有效的新药正进入临床,很大程度改善了MM患者的预后。我们自2005年开始将硼替佐米应用于临床,现对其疗效及安全性进行回顾性分析。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第7期485-486,共2页 Chinese Journal of Hematology
  • 相关文献

参考文献7

  • 1Tcrpos E,Rousseu M,Dimopoulos MA.Bortezomib in multiple myeloma.Expert Opin Drug Metab Toxicol,2008,4:639-654. 被引量:1
  • 2Blade J,Samsen D,Reece D,et al,Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hemopoietic stem cell transplantation.Br J Haematol,1998,102:1115-1123. 被引量:1
  • 3王焰.NF-κB与多发性骨髓瘤[J].国外医学(输血及血液学分册),2003,26(3):244-246. 被引量:12
  • 4Jagannath S,Barlogie B,Berensen J,et al.A phase 2 study of two dose of bortezomib in relapsed or refractory myeloma.Br J Haematol,2004,127:165-172. 被引量:1
  • 5Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of bortezomib in relapsed,refactory myeloma.N Eugl J Med,2003,348:2609-2617. 被引量:1
  • 6San M iguel JF,Schlag R,Khuageva NK,et al.Bortezomib plus melphalan and prednisene for initial treatment of multiple myeloma.N Engl J Med,2008,359:906-917. 被引量:1
  • 7Niesvizky R,Richardson PG,Rajkumar SV,et al.The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international,randomized,phase 3 APEX trial in relapsed multiple myeloma.Br J Haematol,2008,143:46-53. 被引量:1

二级参考文献20

  • 1Hideshima T,Chauhan D,Richardson P,et al. J Biol Chem,2002,277:16639. 被引量:1
  • 2Teicher BA, Ara G, Herbst R, et al. Cancer Res, 1999,59:2638. 被引量:1
  • 3Elliott PJ,Ross JS. Am J Clin Pathol,2001,116:637. 被引量:1
  • 4Garber K. Science, 2002,295 : 612. 被引量:1
  • 5Hideahima T. Cancer Rea,2001,61:3071. 被引量:1
  • 6Stinchcombe TE, Mitchell BS, Depcik - Smith N, et al. Blood, 2001,96:516a. 被引量:1
  • 7May M,J, Ghosh S. Immunol Today, 1998,19:80. 被引量:1
  • 8Baeuerle PA,Baltimore D. Cell, 1996,87:13. 被引量:1
  • 9Barkertt M,Oilomore TD. Oncogene, 1999,18:6910. 被引量:1
  • 10Fracchiolla NS, Lombardi L, Salina M, et al. Oncogene, 1993,8: 2839. 被引量:1

共引文献11

同被引文献28

  • 1扶云碧,孙启鑫,孟凡义,谢军,周光飚.蛋白酶体抑制剂硼替佐米诱导髓系白血病细胞株 HL60凋亡的机制研究[J].中华医学杂志,2006,86(34):2413-2416. 被引量:14
  • 2Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor Ps341.Blood,2003,101:1530-1534. 被引量:1
  • 3Horton TM,Gannavarapu A,Blaney SM,et al.Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.Cancer Chemother Pharmacol,2006,58:13-23. 被引量:1
  • 4Daj Y,Rahmanj M,Pei XY,et al.Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and independent mechanisms.Blood,2004,104:509-518. 被引量:1
  • 5Rao RV,Ellerby HM,Bredesen DE.Coupling endoplasmic reticulum stress to the cell death program.Cell Death Differ,2004,11:372-380. 被引量:1
  • 6Ferri KF,Kroemer G.Organelle-specific initiation of cell death pathways.Nat Cell Biol,2001,31:E255-263. 被引量:1
  • 7Gozzetti A,Defina M,Bocchia M,et al.Safety and efficacy of bortezomib,melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.Leuk Res,2010,34:e288 -289. 被引量:1
  • 8Seki N,Toh U,Sayers TJ,et al.Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.Mol Cancer Ther,2010,9:1842-1851. 被引量:1
  • 9Jiang CC,Lucas K,Avery-Kiejda KA,et al.Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.Cancer Res,2008,68:6708-6717. 被引量:1
  • 10Baou M,Kohlhaas SL,Butterworth M,et al.Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.Haematologica,2010,95:1510-1518. 被引量:1

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部